At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
CDI-31244 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Phase 2a Study Evaluating the Safety and Efficacy of Combination Treatment With 2 Weeks of the Non-Nucleoside Inhibitor CDI 31244 Plus 6 Weeks of Sofosbuvir/Velpatasvir in Subjects With Chronic Hepatitis C Genotype 1 Infection
In Brief
A Phase 2 clinical trial evaluating CDI-31244 and SOF/VEL for Chronic Hepatitis C. Completed, enrolled 12 participants across 1 site.
Detailed Summary
Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic hepatitis C (HCV) genotype 1 (GT1) infection
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartJun 2018
Primary CompletionJan 2019
Study CompletionJun 2019
TodayJul 2026
First PostedApr 18, 2018
Enrollment StartJun 26, 2018
Primary CompletionJan 8, 2019
Study CompletionJun 7, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.2 years ago
Interventions
CDI-31244drug
investigational drug
SOF/VELdrug
sofosbuvir and velpatasvir fixed dose combination